Katrina’s Blog™
News and Commentary
on the science and technology of drugs and medical devices, including discovery, development, manufacturing, and regulation.
Being Strategic About Lab Investments
LinkedIn recently asked me to answer the question, “How can you use cost-benefit analysis (CBA) to make informed lab investments?” Their AI explained the basic steps for performing a CBA. However, there was zero context for strategically thinking about a lab...
NSF Research Funding to Build the American Bioeconomy – is it for you?
Executive Order 14081: Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy [1] in September 2022 marked a change in thinking about the U.S. bioeconomy. The order summarizes the situation perfectly: “The...
U.S. Strategy for Innovation – “Out Innovate With Everyone”
The National Advisory Council on Innovation and Entrepreneurship (NACIE) recently issued ten strategic recommendations for strengthening US entrepreneurship. The report highlights three critical areas: growing our future industries, accessing startup funding, and...
Outbreak – Four Years Later
March 2024 marks four years since the coronavirus outbreak and the global pandemic lockdown started. I wrote several articles spanning February – April 2020, sharing information and making some projections. This is a good time to reflect on the past and what we’ve...
Talent Acquisition and Retention is Broken!
The COVID-19 pandemic has highlighted many flaws in talent acquisition and retention strategies. Companies cannot find suitable candidates to fill positions, yet skilled individuals still need to get a callback after submitting their applications. It's taking weeks to...